Novo Nordisk A/S (NYSE:NVO) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Novo Nordisk A/S (NYSE:NVO) announced its earnings results on Wednesday. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.19, Zacks reports. The business had revenue of $11.98 billion for the quarter, compared to analyst estimates of $10.89 billion. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%.

Here are the key takeaways from Novo Nordisk A/S’s conference call:

• Q2 sales rose 7% to DKK 78.5 billion at constant exchange rates, while adjusted operating profit increased 11%, driven by GLP-1 volume growth and cost discipline.
• The Wegovy pill launch showed strong momentum, reaching approximately 1.5 million global users and capturing about 90% of the U.S. oral obesity-treatment market; early launches in the U.K. and UAE also expanded Novo’s obesity market share.
• Despite volume growth, lower realized prices and access pressures remain significant, particularly in the U.S., where Wegovy injectable sales declined 22% at constant exchange rates and self-pay growth came at lower price points. Novo also expects intensifying competition, Medicaid coverage reductions, and semaglutide patent expiries to weigh on results.
• Novo raised its 2026 outlook, now expecting adjusted sales and operating profit growth of 0% to -6% at constant exchange rates, while cautioning that second-half headwinds include adverse comparisons, loss of exclusivity, pricing pressure, and continued investment.
• The ZEUS cardiovascular outcomes trial for ziltivekimab failed to reduce major adverse cardiovascular events, with a hazard ratio of 0.99, and showed more serious infections; however, Novo plans to continue related cardiovascular studies and advance its broader obesity and diabetes pipeline.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock traded up $1.25 during midday trading on Friday, hitting $47.22. 7,738,455 shares of the company were exchanged, compared to its average volume of 18,204,100. The firm has a 50 day simple moving average of $46.96 and a 200-day simple moving average of $45.01. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm has a market cap of $210.85 billion, a P/E ratio of 11.54, a PEG ratio of 4.06 and a beta of 0.76. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be given a dividend of $0.5786 per share. This represents a dividend yield of 254.0%. The ex-dividend date is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 42.79%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on NVO. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Finally, BMO Capital Markets restated a “market perform” rating and set a $47.00 price target on shares of Novo Nordisk A/S in a research note on Thursday. Five equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $65.81.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: A Texas judge dismissed antitrust claims alleging that Novo Nordisk and Eli Lilly improperly blocked access to compounded GLP-1 weight-loss drugs. The ruling reduces a potential legal and regulatory overhang for Novo’s obesity franchise. Lilly and Novo Win a Key GLP-1 Antitrust Fight
• Positive Sentiment: Novo raised its full-year sales and profit outlook, with management citing continued demand for Wegovy and broader international obesity-care growth. Analysts noted that second-quarter revenue and earnings exceeded expectations, while cost reductions supported operating-profit growth. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
• Positive Sentiment: The company declared a dividend of $0.5786 per share for shareholders of record August 17, payable August 25, providing a near-term shareholder return.
• Neutral Sentiment: CEO Mike Doustdar and CFO leadership are attempting to reset expectations and rebuild investor confidence after a difficult period, emphasizing more disciplined execution and sustainable growth rather than relying solely on explosive Wegovy expansion. Novo Nordisk CEO resets expectations for Wegovy’s explosive growth
• Neutral Sentiment: Novo appointed Omnicom as its U.S. media-buying agency of record, a marketing change that could support brand promotion but has limited immediate financial impact. Novo Nordisk makes Omnicom agency of record for US media buying
• Negative Sentiment: Investor reaction remains pressured by Wegovy pill sales of about $497 million, which narrowly missed expectations. Slower-than-hoped momentum, U.S. pricing pressure, patent losses and product-development setbacks have raised doubts about the outlook despite the guidance increase. The divide between Eli Lilly and Novo Nordisk is widening
• Negative Sentiment: Eli Lilly’s stronger obesity-drug performance is widening the perceived competitive gap, leaving Wall Street less confident in Novo Nordisk even though both companies beat quarterly estimates and raised guidance. Novo Nordisk NVO stock prediction: $64 bull vs $32 bear

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Revolve Wealth Partners LLC increased its position in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after buying an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after buying an additional 1,587 shares in the last quarter. Invesco Ltd. raised its stake in shares of Novo Nordisk A/S by 26.3% in the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after acquiring an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL bought a new position in shares of Novo Nordisk A/S in the second quarter valued at approximately $314,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.